Mechanisms of withdrawal-associated increases in heroin self-administration: Pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys

Neuropsychopharmacology

Volumn 34, Issue 4, 2009, Pages 899-911

  Negus, S Stevens ^a,b   Rice, Kenner C ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Choice; Corticotropin releasing factor 1 receptors; Dependence; Heroin; Self administration; Withdrawal

Indexed keywords

5' GUANIDINONALTRINDOLE; AMPHETAMINE; ANTALARMIN; CLONIDINE; DIAMORPHINE; DOPAMINE; MORPHINE; MORPHINE SULFATE; NORADRENALIN; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CONTROL; CONTROLLED STUDY; DECISION MAKING; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SCORING SYSTEM; WITHDRAWAL SYNDROME;

ADRENERGIC AGENTS; ADRENERGIC AGONISTS; AMPHETAMINE; ANIMALS; BEHAVIOR, ADDICTIVE; CHOICE BEHAVIOR; CLONIDINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOOD; HEROIN; HEROIN DEPENDENCE; MACACA MULATTA; MALE; MORPHINE; NARCOTIC ANTAGONISTS; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 59949086581     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.127     Document Type: Article

References (64)

1. Acquas E, Carboni E, Di Chiara G (1991). Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur J Pharmacol 193: 133-134.
2. Aghajanian GK (1982). Central noradrenergic neurons: a locus for the functional interplay between alpha-2 adrenoceptors and opiate receptors. J Clin Psychiatry 43: 20-24.
3. Ator NA, Griffiths RR (2003). Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70: S55-S72.
4. Blasig J, Herz A (1977). Precipitated morphine withdrawal in rats as a tool in opiate research. Curr Dev Psychopharmacol 4: 129-149.
5. Broadbear JH, Winger G, Rivier JE, Rice KC, Woods JH (2004). Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology 29: 1112-1121.
6. Brugger S, Sanchez R, Brugger AJ, Martinez JA (1998). ICV administration of CRF blocker (CRF9-41 delta helical) reduces morphine withdrawal in rats. Prog Neuropsychopharmacol Biol Psychiatry 22: 775-785.
7. Carrera MR, Schulteis G, Koob GF (1999). Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Psychopharmacology (Berl) 144: 111-120.
8. Chartoff EH, Mague SD, Barhight MF, Smith AM, Carlezon Jr WA (2006). Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal. J Neurosci 26: 6450-6457.
9. Criner SH, Liu J, Schulteis G (2007). Rapid neuroadaptation in the nucleus accumbens and bed nucleus of the stria terminalis mediates suppression of operant responding during withdrawal from acute opioid dependence. Neuroscience 144: 1436-1446.
10. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000). Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403: 430-434.
11. France CP, Woods JH (1989). Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250: 937-943.
12. Frenois F, Cador M, Caille S, Stinus L, Le Moine C (2002). Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16: 1377-1389.
13. Gellert VF, Holtzman SG (1979). Discriminative stimulus effects of naltrexone in the morphine-dependent rat. J Pharmacol Exp Ther 211: 596-605.
14. Gold MS, Redmond Jr DE, Kleber HD (1979). Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry 136: 100-102.
15. Greenstein RA, Fudala PJ, O'Brien CP (1997). Alternative pharmacotherapies for opiate addiction. In: Lowinson JH, Ruiz P, Millman RB and Langrod JG (eds). Substance Abuse: A Comprehensive Textbook. Williams and Wilkins: Baltimore. pp 415-425.
16. Griffiths RR, Wurster RM, Brady JV (1975). Discrete-trial choice procedure: effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev 27: 357-365.
17. Griffiths RR, Wurster RM, Brady JV (1981). Choice between food and heroin: effects of morphine, naloxone, and secobarbital. J Exp Anal Behav 35: 335-351.
18. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L (1995). Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6: 74-80.
19. Hursh SR, Silberberg A (2008). Economic demand and essential value. Psychol Rev 115: 186-198.
20. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, Duman RS (2000). Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74: 199-208.
21. Jasinski DR, Johnson RE, Kocher TR (1985). Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42: 1063-1066.
22. Katz JL (1986). Effects of clonidine and morphine on opioid withdrawal in rhesus monkeys. Psychopharmacology (Berl) 88: 392-397.
23. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A et al (2004). Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27: 739-749.
24. Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97-129.
25. Koob GF, Vaccarino FJ, Amalric M, Bloom FE (1986). Neurochemical substrates for opiate reinforcement. NIDA Res Monogr 71: 146-164.
26. Kosten TA, Kosten TR (1989). Cocaine abuse and opioid withdrawal. Lancet 2: 165-166.
27. Lu L, Liu D, Ceng X, Ma L (2000). Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12: 4398-4404.
28. Maldonado R, Negus S, Koob GF (1992a). Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology 31: 1231-1241.
29. Maldonado R, Stinus L, Gold LH, Koob GF (1992b). Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261: 669-677.
30. McMahon LR, Sell SL, France CP (2004). Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 308: 111-119.
31. Mello NK (2005). Fischman Memorial Lecture. Evaluation of drug abuse treatment medications: concordance between clinical and preclinical studies. NIDA Res Monogr 185: 82-104.
32. Mello NK, Negus SS, Rice KC, Mendelson JH (2006). Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacol Biochem Behav 85: 744-751.
33. Negus SS (2003). Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with D-amphetamine and flupenthixol. Neuropsychopharmacology 28: 919-931.
34. Negus SS (2005). Interactions between the reinforcing effects of cocaine and heroin in a drug-vs-food choice procedure in rhesus monkeys: a dose-addition analysis. Psychopharmacology (Berl) 180: 115-124.
35. Negus SS (2006). Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther 317: 711-723.
36. Negus SS. Opioid antagonist effects in animal models related to opioid abuse: drug discrimination and drug self-administration. In: Dean R, Bilsky EJ, Negus SS (eds). Opioid Receptors and Antagonists: From Bench to Clinic. Humana Press: New York, NY. (in press)
37. Negus SS, Mello NK (2002). Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther 300: 1111-1121.
38. Negus SS, Mello NK (2004). Effects of chronic methadone treatment on cocaine- and food-maintained responding under second-order, progressive-ratio and concurrent-choice schedules in rhesus monkeys. Drug Alcohol Depend 74: 297-309.
39. Negus SS, Mello NK, Linsenmayer DC, Jones RM, Portoghese PS (2002). Kappa opioid antagonist effects of the novel kappa antagonist 5′- guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berl) 163: 412-419.
40. Nylander I, Vlaskovska M, Terenius L (1995). The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology (Berl) 118: 391-400.
41. O'Brien CP (2006). Drug addiction and drug abuse. In: Brunton L, Lazo J, Parker K (eds). The Pharmacological Basis of Therapeutics. McGraw-Hill: New York. pp 607-628.
42. Rattan AK, Koo KL, Tejwani GA, Bhargava HN (1992). The effect of morphine tolerance dependence and abstinence on immunoreactive dynorphin (1-13) levels in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of the rat. Brain Res 584: 207-212.
43. Redmond Jr DE, Huang YH (1982). The primate locus coeruleus and effects of clonidine on opiate withdrawal. J Clin Psychiatry 43: 25-29.
44. Rosen MI, Wallace EA, Sullivan MC, Stine S, Kosten TR (1992). Use of cocaine to prevent opiate withdrawal. Am J Psychiatry 149: 1609.
45. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
46. Schaefer GJ, Michael RP (1983). Morphine withdrawal produces differential effects on the rate of lever-pressing for brain self-stimulation in the hypothalamus and midbrain in rats. Pharmacol Biochem Behav 18: 571-577.
47. Schulteis G, Stinus L, Risbrough VB, Koob GF (1998). Clonidine blocks acquisition but not expression of conditioned opiate withdrawal in rats. Neuropsychopharmacology 19: 406-416.
48. Seevers MH, Deneau GA (1963). Physiological aspects of tolerance and dependence. In: Root WS and Hofmann FG (eds). Physiological Pharmacology I. Academic Press: New York. pp 565-640.
49. Sell SL, France CP (2002). Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. J Pharmacol Exp Ther 301: 1103-1110.
50. Sell SL, McMahon LR, Koek W, France CP (2005). Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behav Pharmacol 16: 53-58.
51. Skelton KH, Oren D, Gutman DA, Easterling K, Holtzman SG, Nemeroff CB et al (2007). The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. Eur J Pharmacol 571: 17-24.
52. Sparber SB, Meyer DR (1978). Clonidine antagonizes naloxone-induced suppression of conditioned behavior and body weight loss in morphine-dependent rats. Pharmacol Biochem Behav 9: 319-325.
53. Spragg SDS (1940). Morphine addiction in chimpanzees. Comp Psychol Monogr 15: 5-132.
54. Stinus L, Cador M, Zorrilla EP, Koob GF (2005). Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30: 90-98.
55. Stinus L, Le Moal M, Koob GF (1990). Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37: 767-773.
56. Tatum AL, Seevers MH, Collins KH (1929). Morphine addiction and its physiological interpretation based on experimental evidences. J Pharmacol 36: 447-475.
57. Thompson T, Schuster CR (1964). Morphine self-administration, food-reinforced, and avoidance behaviors in rhesus monkeys. Psychopharmacologia 5: 87-94.
58. Tseng LF, Loh HH, Wei ET (1975). Effects of clonidine on morphine withdrawal signs in the rat. Eur J Pharmacol 30: 93-99.
59. Van Bockstaele EJ, Qian Y, Sterling RC, Page ME (2008). Low dose naltrexone administration in morphine dependent rats attenuates withdrawal-induced norepinephrine efflux in forebrain. Prog Neuropsychopharmacol Biol Psychiatry 32: 1048-1056.
60. Walker BM, Koob GF (2008). Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33: 643-652.
61. Walsh SL, Strain EC, Bigelow GE (2003). Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction 98: 427-439.
62. Williams KL, Woods JH (2000). A behavioral economic analysis of concurrent ethanol- and water-reinforced responding in different preference conditions. Alcohol Clin Exp Res 24: 980-986.
63. Woods JH, Gmerek DE (1985). Substitution and primary dependence studies in animals. Drug Alcohol Depend 14: 233-247.
64. Yanagita T (1978). Drug dependence studies in laboratory animals. NIDA Res Monogr 19: 179-190.